A Phase 2 interventional study of Low dose MDMA-assisted therapy and Medium dose MDMA-assisted therapy in Posttraumatic Stress Disorder, sponsored by Lykos Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-05.
Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic — 11 open to participants now, 12 under way, 1 of them phase 3. N-Methyl-3,4-methylenedioxyamphetamine · Stress Disorders, Post-Traumatic.
Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, this one is the 18th largest by enrollment, is one of 2 that started in 2010, is one of 28 in phase 2, and was the 4th registered.
2,688 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 606 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →11 of the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic are open now, in 3 countries. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 21–70
Sunstone Medical · Sites in United States
Ages 18+
Sheba Medical Center · Sites in Israel
Ages 18–75
Johns Hopkins University · Sites in United States
Ages 21+
Bronx VA Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 30 · Phase 3 6
First in 2004; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 69 across 2,202 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 25 across the 38 interventional studies. Of the 22 that completed or were terminated, 16 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 38 have an industry lead sponsor. The 10 most frequent:
This study is registered under Lykos Therapeutics, one of the names counted as Resilient Pharmaceuticals. Under that name alone:
Lykos Therapeutics is the lead sponsor of 28 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
20 studies in Stress Disorders, Post-Traumatic by Resilient Pharmaceuticals: none open now, none under way, none of them phase 3. Of 17 finished, 15 (88%) have results posted.
Among the 20 studies in Stress Disorders, Post-Traumatic by Resilient Pharmaceuticals, this one is the 6th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2010, is one of 13 in phase 2, and was the 4th registered.
Resilient Pharmaceuticals’s Stress Disorders, Post-Traumatic studies by the year they started, since 2004.
4 of the studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06117306Phase 3Healing BreakthroughMDMA-assisted Massed Prolonged Exposure for PTSD | 2027-03 |
| NCT07569159Sunstone MedicalMDMA Therapy in Veterans With PTSD | 2027-04-01 |
| NCT05837845Patricia SuppesMDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder | 2027-05 |
| NCT05732155Guy SchusheimPreliminary Effectiveness of Hybrid Individual and Group MDMA-assisted Therapy for War-related PTSD | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Resilient Pharmaceuticals’s 20 in Stress Disorders, Post-Traumatic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective and reducing PTSD symptoms in veterans with chronic PTSD. The main question it aims to answer is: Do three doses of MDMA reduce PTSD symptoms?
Researchers will compare 30, 75, and 125 mg of MDMA HCl with therapy to see which dose best reduces PTSD symptoms.
Participants will undergo three preparatory non-drug therapy sessions with a male and female co-therapist team, then undergo three day-long MDMA-assisted therapy sessions after receiving an initial dose of 30, 75, or 125 mg MDMA HCl. After each MDMA-assisted therapy session, participants will undergo three integrative therapy sessions.
This study is a randomized, double-blind, dose comparison study with an open-label cross-over segment that will assess the safety and efficacy of MDMA-assisted therapy in veterans with chronic PTSD. Twelve of 24 participants will receive the full dose of 125 mg, six will receive 75 mg and six will receive 30 mg (active placebo dose) of MDMA HCl. An independent rater blind to condition will assess symptoms of PTSD and depression, general quality of life and posttraumatic growth prior to any therapy sessions one month after the second experimental session.
After undergoing three 90-minute non-drug introductory therapy sessions with a male/female co-therapist team, study participants will undergo two eight-hour long experimental sessions scheduled three to five weeks apart, prior to which they will be randomized to receive an initial dose of 30, 75 or 125 mg MDMA HCl , followed by a supplemental dose of half the initial dose 1.5 to 2.5 hours later. Participants will undergo integrative therapy in between each experimental session, including on the day after each session. Vital signs and psychological distress will be measured throughout each experimental session, and suicidality will be assessed throughout the course of the study. Spontaneously reported side effects will be collected on the day of each experimental session, and for six days afterward. PTSD symptoms, symptoms of depression, general psychological function, posttraumatic growth and quality of sleep will be assessed one month after the second experimental session, and the blind will be broken.
Participants who received 125 mg MDMA HCl will continue to have a third experimental session, and they will be assessed two months after the third experimental session.
Participants who received 30 or 75 mg MDMA HCl may take part in an open-label crossover segment that will follow nearly identical procedures, except that there will only be one introductory session prior to the first experimental session. There will be three experimental sessions. Symptoms of PTSD, depression and posttraumatic growth will be assessed at the start of the study. They will also be assessed one month after the second and two months after the third experimental session.
All participants will be assessed 12 months after their final experimental session. PTSD and depression symptoms and posttraumatic growth will be assessed, and participants will complete a questionnaire concerning the costs and benefits of being in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 30 mg midomafetamine HCl (MDMA) with therapy during each of two blinded experimental sessions.
Drug: Low dose MDMA-assisted therapy · Behavioral: Therapy
Participants will receive 75 mg midomafetamine HCl (MDMA) with therapy on each of two blinded experimental sessions.
Drug: Medium dose MDMA-assisted therapy · Behavioral: Therapy
Participants will receive 125 mg midomafetamine HCl (MDMA) with therapy during each of two blinded experimental sessions, followed by a third open label session.
Drug: Full dose MDMA-assisted therapy · Behavioral: Therapy
30 mg midomafetamine HCl administered p.o. once at start of an experimental session. Upon mutual agreement, this may be followed by a supplemental dose of 15 mg 1.5 to 2 hours later
Also known as: MDMA, 3,4-methylenedioxymethamphetamine, midomafetamine
75 mg midomafetamine HCl administered p.o. once at start of an experimental session. Upon mutual agreement, this may be followed by a supplemental dose of 37.5 mg 1.5 to 2 hours later
Also known as: MDMA, 3,4-methylenedioxymethamphetamine, midomafetamine
125 mg midomafetamine HCl administered p.o. once at start of an experimental session. Upon mutual agreement, this may be followed by a supplemental dose of 62.5 mg 1.5 to 2 hours later
Also known as: MDMA, 3,4-methylenedioxymethamphetamine, midomafetamine
Non-directive therapy during each session
Change in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to Primary Endpoint
The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.
Time frame: Baseline to one month after second experimental session
Change in Global Assessment of Function (GAF) From Baseline to Primary Endpoint
The Global Assessment of Functioning (GAF) Scale is a numeric scale ranging from 0 through 100 that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. Higher scores indicate better functioning.
Time frame: Baseline to one month after second experimental session
Change in Posttraumatic Growth Inventory (PTGI) From Baseline to Primary Endpoint
The Posttraumatic Growth Inventory (PTGI) is a 21-item self-report measure of perceived growth or benefits occurring after a traumatic event. It contains five subscales; relationship to others, new possibilities, personal strength, spiritual change, and appreciation of life. Questions are answered on a scale from 0 (I did not experience this change) to 5 (I experienced this change to a great degree). Items are added to calculate the total PTGI score which ranges from 0 to 105, with higher scores indicative of greater growth.
Time frame: Baseline to one month after second experimental session
Change in Beck Depression Inventory (BDI-II) From Baseline to Primary Endpoint
Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The BDI-II is scored by summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The maximum total score is 63.
Time frame: Baseline to one month after second experimental session
Change in Dissociative Experience Scale (DES-II) From Baseline to Primary Endpoint
The DES-II is a 28-item self-report measure of dissociation, defined as a lack of normal integration of an individual's thoughts, feelings, or experiences into the stream of consciousness or memory. Respondents indicate how often the specific experience happens to them, from "never" (0% of the time) to "always" (100%). The scale is scored by treating percentages as single digits and summing to produce a total score, ranging from 0 to 100. The higher the score, the more dissociative symptoms.
Time frame: Baseline to one month after second experimental session
Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to Primary Endpoint
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.
Time frame: Baseline to one month after second experimental session
| Milestone | Low Dose MDMA (30 mg) | Medium Dose MDMA (75 mg) | Full Dose MDMA (125 mg) |
|---|---|---|---|
| Started | 7 | 7 | 12 |
| Completed primary endpoint | 7 | 7 | 12 |
| Completed stage 1 | 6 | 6 | 12 |
| Completed stage 2 | 6 | 6 | 0 |
| Completed | 6 | 7 | 11 |
| Not completed | 1 | 0 | 1 |
The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.
| score on a scale | Low Dose MDMA (30 mg) | Medium Dose MDMA (75 mg) | Full Dose MDMA (125 mg) |
|---|---|---|---|
| Change in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to Primary Endpoint | -11.4 ± 12.7 | -58.3 ± 9.8 | -44.3 ± 28.7 |
The Global Assessment of Functioning (GAF) Scale is a numeric scale ranging from 0 through 100 that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. Higher scores indicate better functioning.
| score on a scale | Low Dose MDMA (30 mg) | Medium Dose MDMA (75 mg) | Full Dose MDMA (125 mg) |
|---|---|---|---|
| Change in Global Assessment of Function (GAF) From Baseline to Primary Endpoint | 1.1 ± 4.6 | 19.4 ± 6.1 | 18.4 ± 14.4 |
The Posttraumatic Growth Inventory (PTGI) is a 21-item self-report measure of perceived growth or benefits occurring after a traumatic event. It contains five subscales; relationship to others, new possibilities, personal strength, spiritual change, and appreciation of life. Questions are answered on a scale from 0 (I did not experience this change) to 5 (I experienced this change to a great degree). Items are added to calculate the total PTGI score which ranges from 0 to 105, with higher scores indicative of greater growth.
| score on a scale | Low Dose MDMA (30 mg) | Medium Dose MDMA (75 mg) | Full Dose MDMA (125 mg) |
|---|---|---|---|
| Change in Posttraumatic Growth Inventory (PTGI) From Baseline to Primary Endpoint | -11.6 ± 12.2 | 36.1 ± 12.0 | 33.7 ± 24.0 |
Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The BDI-II is scored by summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The maximum total score is 63.
| score on a scale | Low Dose MDMA (30 mg) | Medium Dose MDMA (75 mg) | Full Dose MDMA (125 mg) |
|---|---|---|---|
| Change in Beck Depression Inventory (BDI-II) From Baseline to Primary Endpoint | -4.6 ± 8.8 | -15.4 ± 9.5 | -24.6 ± 10.6 |
The DES-II is a 28-item self-report measure of dissociation, defined as a lack of normal integration of an individual's thoughts, feelings, or experiences into the stream of consciousness or memory. Respondents indicate how often the specific experience happens to them, from "never" (0% of the time) to "always" (100%). The scale is scored by treating percentages as single digits and summing to produce a total score, ranging from 0 to 100. The higher the score, the more dissociative symptoms.
| score on a scale | Low Dose MDMA (30 mg) | Medium Dose MDMA (75 mg) | Full Dose MDMA (125 mg) |
|---|---|---|---|
| Change in Dissociative Experience Scale (DES-II) From Baseline to Primary Endpoint | 1.8 ± 0.95 | -8.6 ± 1.9 | -8.8 ± 6.2 |
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.
| score on a scale | Low Dose MDMA (30 mg) | Medium Dose MDMA (75 mg) | Full Dose MDMA (125 mg) |
|---|---|---|---|
| Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to Primary Endpoint | 1.8 ± 2.8 | -6.4 ± 7.1 | -4.8 ± 4.1 |
Collected over During entire study duration (approx 12 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Blinded Low Dose MDMA-assisted Therapy | 0/7 (0%) | 1/7 (14.3%) | 6/7 (85.7%) |
| Blinded Medium Dose MDMA-assisted Therapy | 0/7 (0%) | 0/7 (0%) | 4/7 (57.1%) |
| Blinded Full Dose MDMA-assisted Therapy | 0/12 (0%) | 0/12 (0%) | 8/12 (66.7%) |
| Open-Label Low Dose MDMA-assisted Therapy | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Open-Label Medium Dose MDMA-assisted Therapy | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Open-Label Full Dose MDMA-assisted Therapy | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| Low Dose Group 12 Month Follow-Up | 0/6 (0%) | 1/6 (16.7%) | 0/6 (0%) |
| Medium Dose Group 12 Month Follow-Up | 0/7 (0%) | 1/7 (14.3%) | 0/7 (0%) |
| Full Dose Group 12 Month Follow-Up | 0/11 (0%) | 0/11 (0%) | 0/11 (0%) |
| SRRS: Low Dose | 0/7 (0%) | 0/7 (0%) | 7/7 (100%) |
| SRRs: Medium Dose | 0/7 (0%) | 0/7 (0%) | 7/7 (100%) |
| SRRs: Full Dose | 0/12 (0%) | 0/12 (0%) | 12/12 (100%) |
| Event | Blinded Low Dose MDMA-assisted Therapy | Blinded Medium Dose MDMA-assisted Therapy | Blinded Full Dose MDMA-assisted Therapy | Open-Label Low Dose MDMA-assisted Therapy | Open-Label Medium Dose MDMA-assisted Therapy | Open-Label Full Dose MDMA-assisted Therapy | Low Dose Group 12 Month Follow-Up | Medium Dose Group 12 Month Follow-Up | Full Dose Group 12 Month Follow-Up | SRRS: Low Dose | SRRs: Medium Dose | SRRs: Full Dose |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Major DepressionPsychiatric disorders | 0/7 | 0/7 | 0/12 | 0/6 | 0/6 | 0/12 | 1/6 | 0/7 | 0/11 | — | — | — |
| Ventricular extrasystolesCardiac disorders | 0/7 | 0/7 | 0/12 | 1/6 | 0/6 | 0/12 | 0/6 | 0/7 | 0/11 | — | — | — |
| Suicidal IdeationPsychiatric disorders | 1/7 | 0/7 | 0/12 | 0/6 | 0/6 | 0/12 | 0/6 | 0/7 | 0/11 | — | — | — |
| AppendicitisInfections and infestations | 0/7 | 0/7 | 0/12 | 0/6 | 0/6 | 0/12 | 0/6 | 1/7 | 0/11 | — | — | — |
| Event | Blinded Low Dose MDMA-assisted Therapy | Blinded Medium Dose MDMA-assisted Therapy | Blinded Full Dose MDMA-assisted Therapy | Open-Label Low Dose MDMA-assisted Therapy | Open-Label Medium Dose MDMA-assisted Therapy | Open-Label Full Dose MDMA-assisted Therapy | Low Dose Group 12 Month Follow-Up | Medium Dose Group 12 Month Follow-Up | Full Dose Group 12 Month Follow-Up | SRRS: Low Dose | SRRs: Medium Dose | SRRs: Full Dose |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 2/7 | 0/7 | 0/12 | 0/6 | 0/6 | 0/12 | 0/6 | 0/7 | 0/11 | 6/7 | 7/7 | 10/12 |
| Need More SleepGeneral disorders | 0/7 | 0/7 | 0/12 | 0/6 | 0/6 | 0/12 | 0/6 | 0/7 | 0/11 | 6/7 | 6/7 | 9/12 |
| AnxietyNervous system disorders | 1/7 | 0/7 | 1/12 | 2/6 | 0/6 | 0/12 | 0/6 | 0/7 | 0/11 | 4/7 | 5/7 | 10/12 |
| InsomniaNervous system disorders | 0/7 | 0/7 | 1/12 | 0/6 | 0/6 | 1/12 | 0/6 | 0/7 | 0/11 | 5/7 | 3/7 | 10/12 |
| HeadacheGeneral disorders | 0/7 | 0/7 | 0/12 | 0/6 | 0/6 | 0/12 | 0/6 | 0/7 | 0/11 | 2/7 | 3/7 | 7/12 |
| Muscle TensionGeneral disorders | 0/7 | 0/7 | 0/12 | 0/6 | 0/6 | 0/12 | 0/6 | 0/7 | 0/11 | 2/7 | 3/7 | 7/12 |
| Increased IrritabilityGeneral disorders | 0/7 | 0/7 | 0/12 | 0/6 | 0/6 | 0/12 | 0/6 | 0/7 | 0/11 | 4/7 | 2/7 | 6/12 |
| Sleep deficitNervous system disorders | 1/7 | 0/7 | 0/12 | 3/6 | 0/6 | 0/12 | 0/6 | 0/7 | 0/11 | 0/7 | 0/7 | 0/12 |
| Lack of AppetiteGeneral disorders | 0/7 | 0/7 | 0/12 | 0/6 | 0/6 | 0/12 | 0/6 | 0/7 | 0/11 | 2/7 | 1/7 | 6/12 |
| Low MoodGeneral disorders | 0/7 | 0/7 | 0/12 | 0/6 | 0/6 | 0/12 | 0/6 | 0/7 | 0/11 | 3/7 | 0/7 | 3/12 |
Intent-to-treat
| Age, Continuous(years) | Low Dose MDMA (30 mg) | Medium Dose MDMA (75 mg) | Full Dose MDMA (125 mg) | Total |
|---|---|---|---|---|
| Mean | 39.2 ± 9.7 | 29.1 ± 4.0 | 40.7 ± 11.1 | 37.2 ± 10.3 |
| Sex: Female, Male(Participants) | Low Dose MDMA (30 mg) | Medium Dose MDMA (75 mg) | Full Dose MDMA (125 mg) | Total |
|---|---|---|---|---|
| Female | 2 | 1 | 4 | 7 |
| Male | 5 | 6 | 8 | 19 |
| Race/Ethnicity, Customized(Participants) | Low Dose MDMA (30 mg) | Medium Dose MDMA (75 mg) | Full Dose MDMA (125 mg) | Total |
|---|---|---|---|---|
| Ethnicity — White/Caucasian | 6 | 4 | 12 | 22 |
| Ethnicity — Latino/Hispanic | 1 | 1 | 0 | 2 |
| Ethnicity — Native American | 0 | 1 | 0 | 1 |
| Ethnicity — Other | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — We will share de-identified outcome data appearing in any published reports upon request. IPD may include de-identified baseline, demographic and outcome measure data. To ensure participant privacy, it will never include PHI. Please contact the central trial contact for details about data sharing and data available.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data and study-related documents will be available following primary publication of outcomes.
Access criteria: Interested persons should correspond with the central contact for the study.
Ran from Nov 2010 to primary completion in Jun 2015, 54 months.
Results were first posted in Feb 2022, 6 years 7 months after primary completion. A results delay was requested in Mar 2017.
Of 31 industry-sponsored phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 54 months is above that.
Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine
Stress Disorders, Post-Traumatic →